You know that you will lose 20% of your weight using one of these GLP-1 drugs, from Eli Lilly, Novo Nordisk , or Regeneron.
Eli Lilly's retatrotide drug achieved a 28% weight loss, with patients reporting improvements in daily mobility.
We will move from a company with a market value of about one billion dollars to a company with a market value of more than one trillion dollars, which is Eli Lilly. I don't need to explain what Eli Lilly benefits from; the positive momentum is of course the weight loss treatments that have created a sales boom, which reminds me of the sales boom of artificial intelligence companies like Nvidia and Micron.
moving on to the second purchase, we actually have to stay within the pharmaceutical sector for another name that has achieved, if you believe it, an even greater rise. It's kind of crazy.
This name is the recently trillion-dollar pharmaceutical giant, Eli Lilly, whose trading symbol is “LLY”, in which Saudi Arabia has nearly doubled its investments this quarter, pumping about $28 million into this center.
Although Eli Lilly was the second company to introduce oral pills for weight loss treatments, it had already begun to acquire a significant market share. The company boasted a market share exceeding 30% in new initiations within the oral GLP-1 drug sector , identifying more than 36,000 people.
